Sector Expert: Randy Milby

Randy Milby was appointed chief executive officer of CorMedix in January 2013. He joined CorMedix in May 2012 as chief operating officer. Previously, Mr. Milby was cofounder and a managing director of WaterStone Bridge LLC, a healthcare consulting services firm. During his 11-year tenure at DuPont Co., he held several management positions, the most recent as global business director, Applied Biosciences. From 19981999, Mr. Milby was a healthcare analyst at Goldman Sachs. Mr. Milby received his pharmacy degree at the University of Kansas, and his master's degree in business administration from Washington University in St. Louis.



Recent Interviews

CorMedix Transformative Anti-Infective Technology for Catheters Developed to Decrease Serious Drug-Resistant Infections: CEO Randy Milby (2/11/16)
beakerhand630

Patients on dialysis and cancer patients with indwelling catheters live with the possibility of contracting drug-resistant infections that can become more life threatening than their primary diseases. CorMedix Inc. (CRMD:NYSE.MKT) is developing a platform that has shown impressive results in preventing serious bloodstream infections. In this interview with The Life Sciences Report, CorMedix CEO Randy Milby addresses his company's science, pipeline and market opportunity. Chief Scientific Officer and Cofounder Antony Pfaffle, an internist who practiced nephrology, joins the conversation to relate his experience managing chronically ill patients undergoing catheter-based therapies in the critical care setting.



Due to permission requirements, not all quotes are shown.